SubsidieMeestersIntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
Projectdetails
Introduction
What if we could finally treat metastatic patients and uncurable cancers like sarcomas? HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy.
Innovation Background
This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive, and eco-friendly platform. ONCO-Boost can cure hard-to-treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments.
Treatment Method
Our cure is injected intravenously, and this changes everything. We can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors.
Competitive Advantage
As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection.
Company Ambition
HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 6.910.955 |
Tijdlijn
| Startdatum | 1-5-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- HEPHAISTOS-PHARMApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment. | ERC POC | € 150.000 | 2022 | Details |
Live biotherapeutics to potentiate cancer immunotherapyThe project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models. | ERC POC | € 150.000 | 2023 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC POC | € 150.000 | 2023 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC POC | € 150.000 | 2023 | Details |
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.
This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment.
Live biotherapeutics to potentiate cancer immunotherapy
The project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models.
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.